Myriad Genetics Inc. finished a busy year with the announcement that the UK's National Institute for Health and Care Excellence (NICE) now recommends Myriad's EndoPredict multigene breast cancer prognostic test to help physicians guide chemotherapy decisions for patients with ER-positive, HER2-negative, lymph node-negative early breast cancer.
NICE concludes that the current clinical evidence justifies recommending that National Health Service physicians use Myriad's EndoPredict, Genomic Health Inc's Oncotype DX breast recurrence score, or NanoString Technologies...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?